Open Accessibility Menu

Spinal Tumor Treatment in Washington DC

We Treat All Types of Spinal Tumors

Spinal tumors may be cancerous or non-cancerous. The treatment of benign tumors depends on patient symptoms such as pain or lack of mobility, and may be treated with a watch-and-wait approach, various medications, radiation, or surgery. Cancerous tumors can be treated with radiation or chemotherapy, but if these fail, surgery can often be used to relieve pain, stabilize the spine, and to improve quality of life.

Spinal tumors that arise from the spine itself are divided into three categories, depending on where they originate in the spinal cord. Many spinal tumors are benign and cause problems largely because they interfere with nerve conduction or with the structure of the spine:

  • Intradural-extramedullary: menigioma, schwannoma, neurofibroma, nerve root tumors
  • Intramedullary: astrocytoma, ependymoma, lipoma

Metastatic Spinal Tumor

The skeletal spine is often a site for metastasis (spread) from cancers that originate elsewhere in the body. The vertebrae are commonly affected by metastasized lung, breast, and prostate cancers. Metastatic cancers of the bony portion of the spine can often be successfully managed with radiation therapy, especially for pain relief. Bone-building drugs, such as agents used to treat osteoporosis, along with continued chemotherapy, can also help to slow or stop the progress of bone metastases for a significant period.

Clinical Trials

  • WIZARD: A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

    This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. One of the primary outcome measures is to assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the Overall Survival of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.Overall survival is defined as the interval between randomization and death from any cause

  • A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects with Epilepsy with a Predictable Seizure Pattern

    This is a multi-center, double-blind, randomized, parallel group, dose-ranging study to investigate the efficacy and clinical usability of STAP-001 in adult (18 years of age and older) subjects with epilepsy with a predictable seizure pattern. These subjects have an established diagnosis of focal or generalized epilepsy with a documented history of predictable seizure episodes. This is an in-patient study. The subjects will be admitted to a Clinical Research Unit (CRU) or Epilepsy Monitoring Unit (EMU) for study participation. The duration of the stay in the in-patient unit will be 2-8 days. One seizure event per subject will be treated with study medication. The duration and timing of the seizure event and occurrence of subsequent seizures will be assessed by the Staff Caregiver(s)1 through clinical observation and confirmed with video electroencephalogram (EEG).

  • Malignant Brain Tumors
    A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients with Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study This single arm trial is being conducted to establish the safety and efficacy of Gliolan® (5-ALA) in patients undergoing resection of newly diagnosed or recurrent malignant gliomas. The rationale for the study is that Gliolan® (5-ALA), as an adjunct to tumor resection, is safe and will provide surgeons with real-time visualization of malignant tumor.